Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model
One of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. This paper describes the use of dehydrothyrsiferol (DT), iso...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1660-3397/23/1/13 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588054298099712 |
|---|---|
| author | Atteneri López-Arencibia Carlos J. Bethencourt-Estrella Desirée San Nicolás-Hernández Rubén L. Rodríguez-Expósito Angélica Domínguez-de-Barros Lizbeth Salazar-Villatoro Maritza Omaña-Molina Francisco Cen-Pacheco Ana R. Díaz-Marrero José J. Fernández Elizabeth Córdoba-Lanús Jacob Lorenzo-Morales José E. Piñero |
| author_facet | Atteneri López-Arencibia Carlos J. Bethencourt-Estrella Desirée San Nicolás-Hernández Rubén L. Rodríguez-Expósito Angélica Domínguez-de-Barros Lizbeth Salazar-Villatoro Maritza Omaña-Molina Francisco Cen-Pacheco Ana R. Díaz-Marrero José J. Fernández Elizabeth Córdoba-Lanús Jacob Lorenzo-Morales José E. Piñero |
| author_sort | Atteneri López-Arencibia |
| collection | DOAJ |
| description | One of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. This paper describes the use of dehydrothyrsiferol (DT), isolated from the red alga <i>Laurencia viridis</i>, in a pharmaceutical form supported on Sepigel, and the in vivo efficacy against a mouse model of cutaneous leishmaniasis. Studying the ultrastructural effect of DT was also carried out to verify the suspected damage at the cellular level and determine the severity of damages produced in the homeostasis of promastigotes. BALB/c mice infected with <i>Leishmania amazonensis</i> were divided into four groups: untreated mice, mice treated with miltefosine orally and mice treated topically with 1% and 0.5% DT-Sepigel; treatment was carried out for two weeks. Treatment with DT significantly reduced the parasite load in skin, liver and spleen compared with the untreated group. In addition, DT-Sepigel at the lowest concentration (0.5%) showed the best results, reducing lesion size by 87% at 3 weeks post-treatment. DT-Sepigel has demonstrated to be a potent topical treatment that, in combined drug trials, may aim at combating cutaneous leishmaniasis. |
| format | Article |
| id | doaj-art-4a6a9a01b7a74736968ebbd7e2f40f10 |
| institution | Kabale University |
| issn | 1660-3397 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj-art-4a6a9a01b7a74736968ebbd7e2f40f102025-01-24T13:39:28ZengMDPI AGMarine Drugs1660-33972024-12-012311310.3390/md23010013Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine ModelAtteneri López-Arencibia0Carlos J. Bethencourt-Estrella1Desirée San Nicolás-Hernández2Rubén L. Rodríguez-Expósito3Angélica Domínguez-de-Barros4Lizbeth Salazar-Villatoro5Maritza Omaña-Molina6Francisco Cen-Pacheco7Ana R. Díaz-Marrero8José J. Fernández9Elizabeth Córdoba-Lanús10Jacob Lorenzo-Morales11José E. Piñero12Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, SpainInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, SpainInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, SpainInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, SpainInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, SpainDepartamento de Infectómica y Patogénesis Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de Mexico 07360, MexicoDepartamento de Infectómica y Patogénesis Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de Mexico 07360, MexicoInstituto Universitario de Bio-Orgánica Antonio González (IUBO AG), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez 2, 38206 La Laguna, SpainInstituto Universitario de Bio-Orgánica Antonio González (IUBO AG), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez 2, 38206 La Laguna, SpainInstituto Universitario de Bio-Orgánica Antonio González (IUBO AG), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez 2, 38206 La Laguna, SpainInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, SpainInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, SpainInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, SpainOne of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. This paper describes the use of dehydrothyrsiferol (DT), isolated from the red alga <i>Laurencia viridis</i>, in a pharmaceutical form supported on Sepigel, and the in vivo efficacy against a mouse model of cutaneous leishmaniasis. Studying the ultrastructural effect of DT was also carried out to verify the suspected damage at the cellular level and determine the severity of damages produced in the homeostasis of promastigotes. BALB/c mice infected with <i>Leishmania amazonensis</i> were divided into four groups: untreated mice, mice treated with miltefosine orally and mice treated topically with 1% and 0.5% DT-Sepigel; treatment was carried out for two weeks. Treatment with DT significantly reduced the parasite load in skin, liver and spleen compared with the untreated group. In addition, DT-Sepigel at the lowest concentration (0.5%) showed the best results, reducing lesion size by 87% at 3 weeks post-treatment. DT-Sepigel has demonstrated to be a potent topical treatment that, in combined drug trials, may aim at combating cutaneous leishmaniasis.https://www.mdpi.com/1660-3397/23/1/13dehydrothyrsiferolmarine oxasqualenoid<i>Leishmania amazonensis</i>cutaneous leishmaniasis |
| spellingShingle | Atteneri López-Arencibia Carlos J. Bethencourt-Estrella Desirée San Nicolás-Hernández Rubén L. Rodríguez-Expósito Angélica Domínguez-de-Barros Lizbeth Salazar-Villatoro Maritza Omaña-Molina Francisco Cen-Pacheco Ana R. Díaz-Marrero José J. Fernández Elizabeth Córdoba-Lanús Jacob Lorenzo-Morales José E. Piñero Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model Marine Drugs dehydrothyrsiferol marine oxasqualenoid <i>Leishmania amazonensis</i> cutaneous leishmaniasis |
| title | Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model |
| title_full | Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model |
| title_fullStr | Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model |
| title_full_unstemmed | Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model |
| title_short | Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model |
| title_sort | dehydrothyrsiferol against cutaneous leishmaniasis treatment outcome in a murine model |
| topic | dehydrothyrsiferol marine oxasqualenoid <i>Leishmania amazonensis</i> cutaneous leishmaniasis |
| url | https://www.mdpi.com/1660-3397/23/1/13 |
| work_keys_str_mv | AT attenerilopezarencibia dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT carlosjbethencourtestrella dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT desireesannicolashernandez dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT rubenlrodriguezexposito dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT angelicadominguezdebarros dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT lizbethsalazarvillatoro dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT maritzaomanamolina dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT franciscocenpacheco dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT anardiazmarrero dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT josejfernandez dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT elizabethcordobalanus dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT jacoblorenzomorales dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel AT joseepinero dehydrothyrsiferolagainstcutaneousleishmaniasistreatmentoutcomeinamurinemodel |